Contact
Please use this form to send email to PR contact of this press release:
BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
TO:
Please use this form to send email to PR contact of this press release:
BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development
TO: